Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
62 results about "Therapy resistant" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
InactiveUS7973043B2Preventing disease progression/modifyingDelaying/preventing relapseBiocideNervous disorderInitial treatmentTherapy resistant
The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such as a selective serotonin reuptake inhibitor, as initial treatment or as soon as possible. The method targets the prevention of suicide, and provides other benefits including preventing disease progression development of tolerance toward the antidepressants. Another aspect of the invention relates to using the method for alleviating cognitive distortion and related functional impairment or health risks, and / or using the method for smoking cessation or nicotine withdrawal.
Owner:MIGALY PETER
Prognostic and diagnostic method for cancer therapy
InactiveUS20090170715A1Sugar derivativesMicrobiological testing/measurementTherapy resistantCancers diagnosis
The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medulloblastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancer-therapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure. This method can be used to diagnose cancer or predict cancer-therapy outcomes for a variety of cancers. The markers can come from any pathway involved in the regulation of cancer, including specifically the PcG pathway and the “stemness” pathway. The markers can be mRNA, microRNA, DNA, or protein.
Owner:ORDWAY RES INST
Combination therapy for treating hepatitis viral infection
Disclosed are methods of using proteasome inhibitors (PI) in combinations with other pharmaceutically active agents for treating viral hepatitis infections, for example, for treating therapy-resistant and -refractory viral hepatitis infections. Also disclosed are pharmaceutical compositions and kits of pharmaceutical compositions which can be used for treating viral hepatitis infections, for example, for treating therapy-resistant and refractory viral hepatitis infections.
Owner:SCHUBERT ULRICH
P53 vaccines for the treatment of cancers
ActiveUS20070003550A1Promote resultsLimited clinical responseAntipyreticAnalgesicsAntigenTherapy resistant
The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example.
Owner:UNIV OF SOUTH FLORIDA +1
Methods of sensitizing cancer to therapy-induced cytotoxicity
InactiveUS20090148445A1Treating and preventing and inhibiting lymphomaPreventing and inhibiting lymphomaBiocideBoron compound active ingredientsSalinosporamide ATherapy resistant
Owner:TRIPHASE RES & DEV I +1
Prognostic and diagnostic method for disease therapy
Owner:ORDWAY RES INST
Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
InactiveUS20120100109A1Reduce healingImproved prognosisBiocideOrganic active ingredientsTherapy resistantWilms' tumor
The present invention is directed to the administration of an HSV derived oncolytic virus and a PI3K / AKT / mTOR pathway inhibitor to treat various types of resistant tumors. Therapy-resistant tumor formation is one of the main causes for treatment failure in the clinic. The treatment methods and compositions disclosed herein sensitize resistant tumors to the treatment of herpes simplex virus (HSV)-based oncolytic virotherapy. Pre or co-treatment of resistant tumor cells with the mTOR inhibitor, rapamycin, or certain PI3K inhibitors, such as LY294002, can efficiently sensitize the tumors to HSV derived oncolytic viruses, whereby the replication and spread of the viruses are dramatically enhanced.
Owner:HOUSTON SYST UNIV OF
Compositions and methods of treating therapy resistant cancer and uses thereof
ActiveUS20140010879A1Powder deliveryPharmaceutical non-active ingredientsTherapy resistantActive agent
The present disclosure is directed to a composition for the sustained-release delivery of an active agent to a target cell of an individual. The compositions disclosed herein comprise of at least one porous particle; at least one polymer; and at least one active agent. In an embodiment, the porous particle comprises a plurality of microscale reservoirs. In an exemplary embodiment, the at least one active agent is covalently linked to the at least one polymer to form a polymer-active agent conjugate, and the polymer-active agent conjugate is contained in the plurality of microscale reservoirs of the porous particle. The present disclosure is also directed to a method of treating a tumor, comprising the step of administering to an individual the composition described supra. Additionally, disclosed herein is a method of eliminating tumor stem cells. Furthermore, there is provided a method of circumventing multi-drug resistance in a tumor cell.
Owner:THE METHODIST HOSPITAL
Materials and methods for treating oncological disorders
ActiveUS8227434B1Prevent reduce developmentInhibiting cholesterol synthesisCarbohydrate active ingredientsFermentationDiseaseTherapy resistant
The subject invention pertains to materials and methods for treating oncological disorders. The subject invention also pertains to materials and methods for preventing or reducing the development by cancer cells of resistance to an anticancer therapy, such as chemotherapy, radiotherapy and / or immunotherapy. In one embodiment, a patient is treated with an agent that inhibits cholesterol synthesis or that prevents or reduces the increase in cholesterol synthesis observed in therapy-resistant cancer cells. In another embodiment, a patient is treated with an agent that increases the expression, activity, or amount of a Bim protein in a cell. In another embodiment, a patient is treated with an agent to inhibit or reduce cancer cell adhesion to extracellular matrices or stromal cells. In another embodiment, a patient is treated with an agent to inhibit expression of a gene of function of a protein of the FANC / BRCA pathway. In a further embodiment, a patient is treated with an agent to prevent or reduce the DNA crosslink repair function of a cell.
Owner:H LEE MOFFITT CANCER CENT & RES INST INC +1
Targeting trastuzumab-resistant her2+ breast cancer with a her3-targeting nanoparticle
InactiveUS20160060316A1Organic active ingredientsFusion with DNA-binding domainTherapy resistantAnti her2
Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy; and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence
Owner:CEDARS SINAI MEDICAL CENT
Methods for treating therapy-resistant tumors
This invention provides methods for using novel substituted pyrimidine compounds, derivatives and analogs thereof to treat diseases such as cancer. Examples of compounds and derivatives for use in the methods are (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl L-alaninylphosphoramidate and (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl L-alaninyl monophosphate.
Owner:CELMED ONCOLOGY USA
Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle
InactiveUS9850293B2Organic active ingredientsFusion with DNA-binding domainTherapy resistantAnti her2
Owner:CEDARS SINAI MEDICAL CENT
Gamma-glutamyl transpeptidase inhibitors and methods of use
InactiveUS20100197745A1High sensitivityGood effectBiocideAnimal repellantsTherapy resistantCancer cell
The present invention enhances the effects of antitumor agents and increases the sensitivity of therapy-resistant tumor cells to antitumor agents such as chemotherapeutic agents and radiation. The present invention is thus directed to compositions and methods for inhibiting and killing neoplastic cancer cells, for example for the treatment, inhibition or prevention of tumors or malignant growths or other neoplasias in mammals. The GGT inhibitor compounds used in the methods of the present invention comprise a class of benzylthiadiazol benzenesulfoniamides represented by the general structure Formula (I) (FIG. 1), or a pharmaceutically acceptable salt thereof, wherein any one or more of R1-R10 may be H, Cl, F, Br, I, OH, an alkoxy, or NO2. Other R groups include carrier groups linked by C,N, or O. The present invention also provides a method for the prophylaxis or treatment of a reversible airways obstruction in a mammal, such as a human, comprising administration of a therapeutically effective amount of a GGT inhibitor described herein for the prophylaxis or treatment of a disease associated with reverse airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), allergic reaction, respiratory tract infection or upper respiratory tract disease. Other diseases or conditions which may be treated include, for example, degenerative diseases, renal diseases, liver diseases, and inner ear conditions or diseases.
Owner:THE BOARD OF RGT UNIV OF OKLAHOMA
Enterococcus faecalis phage lyase and coding gene and application thereof
InactiveCN103667230AReduce mortalityGood treatment effectAntibacterial agentsPeptide/protein ingredientsTherapy resistantTreatment effect
The invention discloses enterococcus faecalis phage lyase and a coding gene and application thereof. The enterococcus faecalis phage lyase is a protein of the following (a) or (b): (a) protein composed by an amino acid sequence as shown in a sequence 1 of a sequence table; (b) protein which is derived by the sequence 1, has a function of cracking enterococcus faecalis, and is made by the fact that the amino acid sequence as shown in the sequence 1 is subjected to the replacement and / or deletion and / or addition of one or a few of amino acid residue(s). Experiments prove that the lyase protein can crack a variety of kinds of enterococcus faecalis and can be closely combined with the specificity of sensitive bacteria. In addition, animal experiments prove that the lyase has a better treatment effect on the infection caused by enterococcus faecalis, and timely and effective dosage after infection has a certain meaning for reducing the mortality of mice. According to the invention, a foundation for antibiotic replacement therapy resistant to enterococcus faecalis is laid.
Owner:MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
Dock-and-Lock (DNL) Constructs for Human Immunodeficiency Virus (HIV) Therapy
ActiveUS20120082685A1Reduce eliminateReduce and eliminate focusOrganic active ingredientsAntiviralsAntigenCD4 antigen
The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, CD4 and CCR5. In a more preferred embodiment the antibody is P4 / D10 or 2G12, although other anti-HIV antibodies are known and may be utilized. In a most preferred embodiment, the anti-HIV therapeutic agent is a fusion inhibitor, such as T20, T61, T651, T1249, T2635, CP32M or T-1444, although other anti-HIV therapeutic agents are known and may be utilized. The DNL complex may be administered alone or may be co-administered with one or more additional anti-HIV therapeutic agents.
Owner:IBC PHARMACEUTICALS INC
Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers
ActiveUS9132120B1Reducing steady-state levelReduce decreaseOrganic active ingredientsMechanical/radiation/invasive therapiesTherapy resistantAbnormal tissue growth
In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject.In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and / or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.
Owner:UNIV OF MARYLAND +1
Method of treating cancer with an anti-CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8
ActiveUS10550191B2Useful in treatmentReduce countPharmaceutical delivery mechanismImmunoglobulins against cell receptors/antigens/surface-determinantsTherapy resistantAntiendomysial antibodies
Owner:SHIONOGI & CO LTD +1
Targeting trastuzumab-resistant her2+ breast cancer with a her3-targeting nanoparticle
InactiveUS20180066033A1Organic active ingredientsFusion with DNA-binding domainTherapy resistantApoptosis
Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule. Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy; and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence.
Owner:CEDARS SINAI MEDICAL CENT
Prognostic and diagnostic method for cancer therapy
InactiveUS7890267B2Sugar derivativesDigital data processing detailsTherapy resistantCancers diagnosis
The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medulloblastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancer-therapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure. This method can be used to diagnose cancer or predict cancer-therapy outcomes for a variety of cancers. The markers can come from any pathway involved in the regulation of cancer, including specifically the PcG pathway and the “stemness” pathway. The markers can be mRNA, microRNA, DNA, or protein.
Owner:ORDWAY RES INST
Animal model of anxiety and depression
This invention relates generally to animal models of anxiety and depression. Specifically, this invention relates to an in vivo high utility, high-throughput model for screening anxiolytic / antidepressant drugs in fowl chicks with stress vulnerability. This new animal model utilizes an inexpensive avian model, measures spontaneous behaviors in very young animals, and is capable of detecting and / or differentiating a compound's anxiolytic and / or antidepressant effects. This new animal model is especially useful in detecting and / or differentiating a compound's anxiolytic and / or antidepressant effects in treatment-resistant subjects. Animal costs are less than 10% of rodent costs and the assay can be run in a high-throughput mode.
Owner:UNIVERSITY OF MISSISSIPPI
Novel brain glioma molecular typing method
PendingCN112735537AHigh precisionImprove the recovery rate of treatmentHealth-index calculationBiostatisticsTherapy resistantT cell
The invention discloses a novel brain glioma molecular typing method which comprises the following steps: step 1, collecting data, acquiring gene expression profiles and clinical information data from a database, and collecting four independent immunotherapy queues from a public database, including (1) Roh queues: an anti-CTLA4 treatment queue and an anti-PD1 treatment queue; (2) GSE100797: an adoptive T cell treatment queue; and (3) GSE78220: an anti-PD1 treatment queue. the GRI values are obtained through a large amount of data, brain glioma molecules of different patients can be divided, the accuracy of brain glioma molecule division is improved, doctors can be assisted in conducting different types of division on the patients conveniently, scientific treatment is conducted on the patients through different treatment modes, the treatment rehabilitation rate of the patients is increased, and the treatment cost of the patients is reduced. The problem that the traditional brain glioma molecular typing accuracy is low is solved.
Owner:ZHENGZHOU UNIV
P53 vaccines for the treatment of cancers
The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example.
Owner:UNIV OF SOUTH FLORIDA +1
RNA interference sequence aiming at hepatocyte nuclear factor 4a and applications thereof
ActiveCN102304515ARepress transcriptionInhibition of replicationGenetic material ingredientsDigestive systemSide effectHepatocyte nuclear factors
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Use of organic cation transporters for cancer diagnosis and therapy
InactiveUS20100028259A1Microbiological testing/measurementDisease diagnosisTherapy resistantLeaving group
The present invention provides, for the first time, the finding that organic cation transporters (OCTs) are major determinants of the anticancer activity of platinum-based drugs such as oxaliplatin, and therefore have clinical significance for selecting oxaliplatin as the preferred therapy for a cancer that expresses one or more OCTs, such as colorectal cancer or liver cancer. In addition, the OCT genotype can also be used to predict oxaliplatin response or to select therapy. The present invention also provides methods of treating or inhibiting cancers that expresses one or more OCTs by administering a therapeutically effective amount of a platinum-based drug such as an oxaliplatin analog having an organic non-leaving group with an increased size. The present invention further provides methods of sensitizing a therapy resistant cancer to a platinum-based drug such as oxaliplatin by administering a therapeutically effective amount of a nucleic acid encoding an OCT. Compositions, kits, and integrated systems for carrying out the diagnostic, prognostic, and therapeutic methods of the present invention are also provided.
Owner:RGT UNIV OF CALIFORNIA
Breast cancer liver metastasis anti-HER-2 treatment curative effect prediction method, system, equipment and medium
PendingCN114549463AGood classification performanceThe value of good practical applicationImage enhancementImage analysisTherapy resistantTreatment effect
The invention provides a curative effect prediction method, system and device for breast cancer liver metastasis anti-HER-2 treatment and a medium, and belongs to the technical field of medicine. The method comprises the following steps: acquiring a to-be-recognized abdomen enhanced CT image of a subject, namely an anti-HER-2 treated breast cancer liver metastasis patient; and inputting a to-be-identified abdomen-enhanced CT image to the curative effect prediction model, and performing quantitative analysis operation on the to-be-identified abdomen-enhanced CT image by the curative effect prediction model to obtain a curative effect prediction result of the breast cancer liver metastasis anti-HER-2 treatment of the subject. According to the method, the value of the radiomics characteristics based on the abdominal enhanced CT in predicting the anti-HER-2 treatment effect of the BCLM is researched for the first time, so that reference information and related clinical guidance opinions are provided for predicting the anti-HER-2 treatment effect of an HER-2 positive BCLM patient and a total treatment scheme.
Owner:SHANDONG UNIV QILU HOSPITAL
siRNA compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer
ActiveUS9546367B2Shorten the durationReduce severityOrganic active ingredientsSugar derivativesTherapy resistantDisease
Disclosed are methods and compositions for siRNA-mediated therapy of mammalian diseases. In particular, compositions and methods are disclosed for treatment of therapy-resistant human breast cancers. In exemplary embodiments, siRNA molecules are presented that effectively knock down gene expression of one or more polynucleotides in breast cancer tumor initiating cells.
Owner:CHANG JENNY CHEE NING
Composition for prevention or treatment of treatment-resistant cancer
InactiveUS20160361418A1Therapy-resistant cancer can be treated or prevented further efficientlyGood effectEnergy modified materialsLight therapyPhotodynamic therapyTherapy resistant
[Problem to be Solved] It is an object of the present invention to provide a preventive or therapeutic composition for a therapy-resistant cancer having therapy-resistant cancer cells.[Solution] A preventive or therapeutic composition for a therapy-resistant cancer having therapy-resistant cancer cells, which is for use in photodynamic therapy, wherein the composition comprises ALAs.
Owner:SBI PHARMA CO LTD +1
Immune molecule classification system for prostate cancer patients and application thereof
The invention provides an immune molecule classification system for prostate cancer patients and application of the immune molecule classification system, and relates to the technical field of biomedicine. According to the immune molecule classification system for the prostate cancer patient, the prostate cancer patient is divided into three subtypes, namely a non-immune subtype, an immune activation subtype and an immunosuppression subtype, and clinical anti-PD-1 / PD-L1 treatment is determined through classification. The defects in the prior art are overcome, a new classification system basedon immune characteristics is established, three immune phenotypes are established, it is prompted that immune response is a driving factor of prostate cancer prognosis, and a new thought is provided for immunotherapy of prostate cancer patients.
Owner:THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV
Composition for the Treatment of Resistant Cancers Comprising Oridonin
InactiveUS20100016420A1Improved pharmacokinetic propertiesImprove propertiesBiocideAnimal repellantsTherapy resistantHuman cancer
The present invention relates to the treatment of therapy-resistant neoplasias. The compounds and methods of the invention are particularly useful for the treatment of taxol-resistant human cancers, particularly cervical and breast cancer. Components of the compositions of the present invention show strong synergy with one another allowing them to be used in relatively low amounts for the treatment of stage IV or recurrent cancer which may have grown resistant to the traditional chemotherapeutic agents. These compositions comprise oridonin.
Owner:ACTIVEPHYTO TECH LTD
Physiological fluid separation vehicles having improved resistance to inward migration of therapeutic agent
A polyester composition for use in facilitating separation of blood serum or plasma from a cellular portion of blood, the composition containing: (a) a multifunctional acid component comprising: (i) a benzene polycarboxylic acid, and derivatives thereof; and (ii) an aliphatic polycarboxylic acid having from about 16 to about 40 carbon atoms; and (b) a diol component, and wherein the multifunctional acid component and diol component are employed in an equivalent ratio ranging from about 0.8:1.1 to about 1.0:1.3.
Owner:COGNIS CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com